Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin

Psychedelics are increasingly being discussed as potential treatments for several mental disorders, especially depression, and psilocybin has shown encouraging results in clinical trials for treatment-resistant depression. However, the role of psychological support alongside psilocybin remains uncertain: it is not clear whether support is essential to efficacy, which elements of support matter most, or how such support could be delivered within publicly funded services. These uncertainties are particularly important because psilocybin treatment is typically given over several hours and may require substantial staff time and resources. This article, therefore, examines the evidence and practical issues around psilocybin implementation, with a particular focus on how treatment might be delivered in the NHS if the drug is licensed. The authors aim to outline a model for psychological support in real-world public services, drawing on both the current evidence base and their own research experience, and to identify the further research needed to inform safe and equitable clinical deployment.

This is a narrative article rather than an original experimental study, review, or meta-analysis. The authors synthesise evidence from psilocybin trials, regulatory frameworks, and broader psychedelic research to explore implementation issues in publicly funded health services, particularly the NHS. The paper draws on previously reported Phase II and Phase III trial results in treatment-resistant depression, as well as published and press-released findings, to illustrate efficacy and safety. It also refers to a mixed-methods study of people reporting adverse experiences after psychedelic use, and to earlier reviews and meta-analyses on the amount and type of psychological support used in psychedelic treatment. In addition, the authors describe an illustrative implementation approach used by their research group at the Oxford Health Clinical Research Facility, which is one of several UK sites in an ongoing Phase III psilocybin trial. For the illustrative example, the authors explain that the site used experienced research assistants rather than only professionally registered therapists. These staff were psychology graduates with inpatient and outpatient experience and completed the same training as therapists at other trial sites. They delivered preparation sessions, supervised support during the dosing day, and integration sessions afterwards, under close clinical supervision. The paper does not present a formal comparative analysis of this staffing model; instead, it uses the approach as an example of one possible route to NHS implementation.

The paper reports that psilocybin trials in treatment-resistant depression have generally been positive. A Phase II study found that a single 25 mg dose reduced Montgomery-Åsberg Depression Rating Scale scores more than 1 mg at 3 weeks, with a mean difference of -6.6 (95% CI -10.2 to -2.9; P < 0.001). The authors also cite recent Phase III press-release results showing a smaller but still statistically significant effect at 6 weeks: -3.6 (95% CI -5.7 to -1.5; P < 0.001) for 25 mg versus inactive placebo, and -3.8 (95% CI -5.8 to -1.8; P < 0.001) for two 25 mg doses versus 1 mg. Across trials, psilocybin is described as short-term, safe, and generally well tolerated, with common adverse effects including transient headache, dizziness, nausea, and fatigue. The authors note that lower-frequency delayed harms, such as suicidal ideation and hallucinogen persisting perception disorder (HPPD), need ongoing monitoring. They also cite a mixed-methods study of 608 people who self-identified as having experienced difficulties after psychedelic use, with more than 95% of experiences occurring in non-clinical settings; in that study, respondents most commonly described emotional difficulties, and 103 responses referred to problems lasting beyond 3 years. Regarding psychological support, the paper reports that earlier meta-analyses found no clear association between the number of therapy or psychological support hours and depressive outcomes, and no clear dependence on the specific psychological protocol used. However, the authors emphasise that these analyses were limited by inconsistent reporting and missing data. In their own illustrative NHS-oriented model, the authors state that experienced research assistants successfully delivered preparation, dosing-day support and integration sessions under supervision, suggesting that a more readily available mental health workforce may be able to provide the support needed in practice. No formal outcome data for this staffing model are reported in the extracted text.

The authors argue that psilocybin has promising therapeutic potential for treatment-resistant depression, but that real-world implementation depends on resolving major uncertainties about psychological support, regulation and workforce capacity. They frame psychological support as both a safety measure during the acute psychedelic experience and, possibly, an active part of the treatment itself. Because the exact role of support remains unclear, they suggest that current trial models do not yet tell services which components are essential or what minimum ‘dose’ of support is required. The paper places these issues in the context of prior research showing positive efficacy signals, but also inconsistent reporting of psychotherapeutic procedures. The authors note that some reviews have not found a clear relationship between support hours or protocol type and depression outcomes, yet they caution that the evidence base is too incomplete for firm conclusions. They also discuss wider concerns about delayed adverse effects, the need for ongoing monitoring, and the possibility that benefits may not be durable without further treatment. The authors identify several practical limitations for NHS implementation. They highlight regulatory constraints, the high staffing burden of one-to-one support over a 6-8 h dosing session, and the shortage of suitably trained clinicians. They suggest that existing guidance from regulators and professional bodies may restrict delivery to specialist settings and could make widespread NHS provision difficult, potentially pushing access into private care. In response, they describe their own pragmatic staffing model as an example of how support might be delivered by trained, experienced NHS mental health staff under supervision, though they acknowledge that the optimal model remains unknown. For future research, the authors call for mechanistic studies that examine both biological and psychotherapeutic contributors to benefit, and for better reporting of support procedures using frameworks such as TIDieR and ReSPCT. They recommend more comparative studies testing psychedelic treatment alone, psychotherapy/support alone, and combined approaches, as well as a more coordinated research prioritisation process involving multiple stakeholders.